Setting the Scene - Industry. Regulatory Science. Merete Schmiegelow Senior Director, Regulatory Policy

Similar documents
Transcription:

CORS-Industry-241116 1 Regulatory Science Setting the Scene - Industry Merete Schmiegelow Senior Director, Regulatory Policy Honorary Industrial Ambassador in Regulatory Science at the University of Copenhagen Regulatory Science - Present and Future 24 Nov, 2016

CORS-Industry-241116 2 Agenda 1 Industry R&D productivity 2 Industry Regulatory Affairs 3 Industry needs for CORS 4 CORS RS definition and focus

CORS-Industry-241116 3 Development of new therapies to patients are lengthy, expensive and with high risks for investors Drug Discovery Nonclinical testing Clinical Ph 1-3a Submission & Approval HTA & Reimbursement negot. Launch & LCM 3-6 years 6-7 years 2-5 years Total 15 years 1 in 10.000 compounds Total cost to develop and launch: USD 2-4 Billions Source: Tufts - drug development 2014

CORS-Industry-241116 4 R&D productivity reduced over the years Development of new therapies to patients are lengthy, expensive and with high risks for investors Regulatory requirements Industry Response: Development Costs Focus e.g. on how to increase R&D efficiency Number of new drugs approved Increasing Increasing Stagnating

CORS-Industry-241116 5 Agenda 1 Industry R&D productivity 2 Industry Regulatory Affairs 3 Industry needs for CORS 4 CORS RS definition and focus

CORS-Industry-241116 6 Regulatory Affairs in the pharma industry Ensures licence to operate (Q-S-E-P) Apply regulatory science to ensure a strong, reliable, quality-based story line Enables best possible labelling Impacts regulatory framework Pre-requisites Understanding and building the bridge to: regulator s mindset Q-E-S data (context & content driven) HTA/payer mind-sets on regulatory parameters

CORS-Industry-241116 7 Agenda 1 Industry R&D productivity 2 Industry Regulatory Affairs 3 Industry needs for CORS 4 CORS RS definition and focus

CORS-Industry-241116 8 Optimal regulatory impact assume broad competences The industry has identified the regulatory Regulatory Affairs: and regulatory science competences from The internal experts on regulators mindset Danish universities as currently insufficient CMC Manufact. Formulation Control Quality Safety Animals Quality Efficacy Clinical Human safety Benefit/Risk Quality Regulatory Pathways Scientific advice Approval Labelling RS in Decisions Tools Standards Research Performance Predictability Research Development Approvals LCM

CORS-Industry-241116 9 Why Copenhagen Centre Of Regulatory Science A need from the pharmaceutical industry (and regulators): Improved university competences in the regulatory disciplines Increased PhDs/Postdocs within Regulatory Science supporting more evidence based regulatory practice in decision making

CORS-Industry-241116 10 CORS 2014: Unique Public Private - Partnership Academia Industry Regulators Patients with an unmet medical need Mind the gap it s time to jump on the train! Mutual trust is needed to work smarter for the benefit of patients and society

CORS-Industry-241116 11 CORS Scientific Advisory Board (SAB) Multidisciplinary UCph Faculties Health & Med. Science Humanities Law Social Science Patients Rare Diseases Association (in Denmark) Ferring Pharmaceuticals H. Lundbeck A/S LEO Pharma Authorities Danish Health and Medicines Authority Companies Novo Nordisk A/S

CORS-Industry-241116 12 Worldwide RS A ctivities Increase Significantly Lack of efficient evidence based focus and transparency Current frontrunners EU: NL & DK (& PT) US: > 30 RS educations & ~ 9 RS research units Asia: Japan, China, Singapore CORS unique governance Four multidisciplinary parties

CORS-Industry-241116 13 Agenda 1 Industry R&D productivity 2 Industry Regulatory Affairs 3 Industry needs for CORS 4 CORS RS definition and focus

CORS-Industry-241116 14 Copenhagen Center for Regulatory Science (CORS) Medical Product Innovation. Research & Education Definition of Regulatory Science (RS) The science of developing new tools standards approaches to evaluate the efficacy, safety, quality and performance of medical products in order to assess benefit/risk and facilitate a sound and transparent regulatory decision making.

CORS-Industry-241116 15 CORS Multidisciplinary Research Focus Categories Producing tools and standards Science that facilitates regulatory decision making Science that assists regulatory decision making Producing evidence Testing performance Science that evaluates regulatory decision making

Postponed to panel discussions CORS-Industry-241116 16